Amgen Senior VP-Research and Development Joseph Miletich: An Interview With “The Pink Sheet” DAILY (Part 3 of 3)
This article was originally published in The Pink Sheet Daily
Executive Summary
Miletich discusses the firm’s peptibody candidates in therapeutic areas including autoimmune diseases and oncology.
You may also be interested in...
Avastin Stakes Claim In Ovarian Cancer; Other Ovarian Updates At ESMO Are Mixed
Roche is gearing up for a planned year-end submission of Avastin in advanced ovarian cancer in the EU after making a splash at the European Society for Medical Oncology meeting with updated data from its Phase III ICON7 study showing a progression-free survival benefit.
Avastin Stakes Claim In Ovarian Cancer; Other Ovarian Updates At ESMO Are Mixed
Roche is gearing up for a planned year-end submission of Avastin in advanced ovarian cancer in the EU after making a splash at the European Society for Medical Oncology meeting with updated data from its Phase III ICON7 study showing a progression-free survival benefit.
Amgen Reveals Positive Phase III Data For Platelet Drug Romiplostim
Strong efficacy findings should aid company’s race with GSK to get chronic ITP treatment to market.